Skip to content

Bausch Health Companies BHC Debt Issuance Costs

Debt Issuance Costs at other companies

HRO
HarrowHROW
$113K
TG Therapeutics logo
TG TherapeuticsTGTX
$2.6M
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$2.5B+11.7%
Operating income-$950.0M-444%
Net income-$1.4B-2,353%
EPS (diluted)-$3.82-2,287%

Balance sheet

See full
Cash & equivalents$1.3B+13.4%
Total debt$20.8B-3.5%
Total equity-$2.1B-74.0%
Total assets$24.5B-7.3%

Cash flow

See full
Operating cash flow$230.0M+9.0%
CapEx$109.0M-5.2%
Free cash flow$121.0M+26.0%

Valuation

See full
Market cap$1.86B-15.9%

Profitability

See full
Gross margin71.4%
Operating margin5.6%-10.3pp
Net margin-1.9%-0.9pp
FCF margin9.8%-2.8pp

Returns & leverage

See full
Return on equity-70.1%
Debt / equity45.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Bausch Health Companies in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Bausch Health Companies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch Health Companies's debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch Health Companies's debt issuance costs?
Bausch Health Companies (BHC) reported debt issuance costs of $1M in Q1 2026.
How has Bausch Health Companies's debt issuance costs changed year-over-year?
Bausch Health Companies's debt issuance costs decreased by 80.0% year-over-year, from $5M to $1M.
What is the long-term trend for Bausch Health Companies's debt issuance costs?
Over 3 years (2021 to 2025), Bausch Health Companies's debt issuance costs has grown at a -2.1% compound annual growth rate (CAGR), from $48M to $45M.
What does debt issuance costs mean?
Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.